Merck & Co., Inc. Confident on Gardasil as GlaxoSmithKline Rival Nears

Bookmark and Share

Reuters -- Gardasil will continue to dominate the U.S. cervical cancer vaccine market despite the expected launch of a competitor from GlaxoSmithKline, Merck & Co’s chief executive said on Thursday.

MORE ON THIS TOPIC